Targeting KRAS ‐mutant pancreatic cancer through simultaneous inhibition of KRAS , MEK, and JAK2
Molecular Oncology · 2025-02 · 19 (2) · 377-390
DOI: 10.1002/1878-0261.13751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 14.10.2024. Verfasst von Satoru Miyazaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School o…. Hauptthemen laut MEDLINE: Janus Kinase 2, Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms, Mutation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The Kirsten rat sarcoma ( KRAS ) oncogene was considered “undruggable” until the development of sotorasib, a KRAS G12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRAS G12D inhibitor, has shown promising results in basic research, although its effects against pancreatic cancer are limited when used alone. Therefore, there is an urgent need to identify effective drugs that can be used in combination with KRAS inhibitors. In this study, we found that administration of the KRAS inhibitors sotorasib or MRTX1133 upregulated STAT3 phosphorylation and reactivated ERK through a feedback reaction. The addition of the MEK inhibitor trametinib and the JAK2 inhibitor fedratinib successfully reversed this effect and resulted in significant growth inhibition in vitro and in vivo . Analyses of sotorasib‐ and MRTX1133‐resistant cells showed that trametinib plus fedratinib reversed the resistance to sotorasib or MRTX1133. These findings suggest that the JAK2‐mediated pathway and reactivation of the MAPK pathway may play key roles in resistance to KRAS inhibitors in pancreatic cancers. Accordingly, simultaneous inhibition of KRAS, MEK, and JAK2 could be an innovative therapeutic strategy against KRAS ‐mutant pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Surgery, Jinai Hospital, Ina, Japan.
ORCID-Profile: Masato Kitazawa
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Miyazaki, S., Kitazawa, M., Nakamura, S., Koyama, M., Yamamoto, Y., Hondo, N., Kataoka, M., Tanaka, H., Takeoka, M., Komatsu, D., & Soejima, Y. (2025). Targeting KRAS ‐mutant pancreatic cancer through simultaneous inhibition of KRAS , MEK, and JAK2. Molecular Oncology, 19(2), 377-390. https://doi.org/10.1002/1878-0261.13751
Vancouver
Miyazaki S, Kitazawa M, Nakamura S, Koyama M, Yamamoto Y, Hondo N, et al. Targeting KRAS ‐mutant pancreatic cancer through simultaneous inhibition of KRAS , MEK, and JAK2. Molecular Oncology. 2025;19(2):377-390. doi:10.1002/1878-0261.13751
BibTeX
@article{Miyazaki2025,
author = {Miyazaki, Satoru and Kitazawa, Masato and Nakamura, Satoshi and Koyama, Makoto and Yamamoto, Yuta and Hondo, Nao and Kataoka, Masahiro and Tanaka, Hirokazu and Takeoka, Michiko and Komatsu, Daisuke and Soejima, Yuji},
title = {Targeting KRAS ‐mutant pancreatic cancer through simultaneous inhibition of KRAS , MEK, and JAK2},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {2},
pages = {377--390},
doi = {10.1002/1878-0261.13751}
}
EUVIMED